# Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

> **NCT01111851** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Chemotherapy-Induced Nausea and Vomiting (CINV)

## Interventions

- **DRUG:** Fosaprepitant 150 mg
- **DRUG:** Aprepitant 165 mg
- **DRUG:** Aprepitant 250 mg
- **DRUG:** Dexamethasone (12-8-16-16 mg)
- **DRUG:** Dexamethasone (12-8-8-16 mg)
- **DRUG:** Ondansetron
- **DRUG:** MK0999

## Key facts

- **NCT ID:** NCT01111851
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01111851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01111851, "Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01111851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*